ATE202282T1 - Verwendung von glycosaminoglycanen zur herstellung eines arzneimittels zur behandlung des chronischen nierenversagens - Google Patents

Verwendung von glycosaminoglycanen zur herstellung eines arzneimittels zur behandlung des chronischen nierenversagens

Info

Publication number
ATE202282T1
ATE202282T1 AT95113868T AT95113868T ATE202282T1 AT E202282 T1 ATE202282 T1 AT E202282T1 AT 95113868 T AT95113868 T AT 95113868T AT 95113868 T AT95113868 T AT 95113868T AT E202282 T1 ATE202282 T1 AT E202282T1
Authority
AT
Austria
Prior art keywords
peritoneal
glycosaminoglycans
treatment
sulodexide
subjected
Prior art date
Application number
AT95113868T
Other languages
English (en)
Inventor
Bruno Baggio
Giorgio Bazzato
Agostino Fracasso
Giovanni Gambaro
Egidio Marchi
Gianfranco Tamagnone
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of ATE202282T1 publication Critical patent/ATE202282T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95113868T 1994-10-06 1995-09-04 Verwendung von glycosaminoglycanen zur herstellung eines arzneimittels zur behandlung des chronischen nierenversagens ATE202282T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITBO940436A IT1274351B (it) 1994-10-06 1994-10-06 Uso di alcuni glicosaminoglicani nella dialisi peritoneale.

Publications (1)

Publication Number Publication Date
ATE202282T1 true ATE202282T1 (de) 2001-07-15

Family

ID=11340040

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95113868T ATE202282T1 (de) 1994-10-06 1995-09-04 Verwendung von glycosaminoglycanen zur herstellung eines arzneimittels zur behandlung des chronischen nierenversagens

Country Status (9)

Country Link
US (1) US5686432A (de)
EP (1) EP0710483B1 (de)
AT (1) ATE202282T1 (de)
DE (1) DE69521388T2 (de)
DK (1) DK0710483T3 (de)
ES (1) ES2157277T3 (de)
GR (1) GR3036158T3 (de)
IT (1) IT1274351B (de)
PT (1) PT710483E (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
MXPA02000142A (es) * 1999-06-30 2003-07-21 Hamilton Civic Hospitals Res Composiciones de heparina que inhiben los factores de coagulacion asociados con el coagulo.
ITMI991503A1 (it) * 1999-07-08 2001-01-08 Bidifarm S R L Uso di metaboliti oligosaccaridici di proteoglicani come maker in fluidi biologici di diagnosi del biabete e delle complicanze patologiche c
US7259152B2 (en) * 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
JP2004507562A (ja) * 2000-09-08 2004-03-11 ハミルトン　シビック　ホスピタルズ　リサーチ　ディベロップメント　インコーポレイテッド 抗血栓性組成物
US20030008844A1 (en) * 2001-05-17 2003-01-09 Keryx Biopharmaceuticals, Inc. Use of sulodexide for the treatment of inflammatory bowel disease
US20030013680A1 (en) * 2001-06-12 2003-01-16 Keryx Methods using glycosaminoglycans for the treatment of nephropathy
PE20030263A1 (es) * 2001-07-31 2003-04-17 Novartis Ag Composicion farmaceutica oftalmica
US8367731B2 (en) 2005-05-30 2013-02-05 Fresenius Medical Care Deutschland Gmbh Peritoneal dialysis fluid
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
US20070155672A1 (en) * 2006-01-05 2007-07-05 Markus Voges Sterilized peritoneal dialysis solutions containing heparin
CN101883794B (zh) * 2007-10-01 2012-11-07 生化学工业株式会社 低分子化硫酸软骨素及其用途
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
IT1401253B1 (it) * 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
IT1270846B (it) * 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
HU219339B (en) * 1993-09-30 2001-03-28 Seikagaku Kogyo Co Ltd Dermatan sulphate with low heparin or heparane sulphate content and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
US5686432A (en) 1997-11-11
DK0710483T3 (da) 2001-09-03
EP0710483B1 (de) 2001-06-20
EP0710483A1 (de) 1996-05-08
ES2157277T3 (es) 2001-08-16
GR3036158T3 (en) 2001-09-28
DE69521388T2 (de) 2001-10-11
ITBO940436A1 (it) 1996-04-06
ITBO940436A0 (it) 1994-10-06
PT710483E (pt) 2001-09-28
DE69521388D1 (de) 2001-07-26
IT1274351B (it) 1997-07-17

Similar Documents

Publication Publication Date Title
ATE202282T1 (de) Verwendung von glycosaminoglycanen zur herstellung eines arzneimittels zur behandlung des chronischen nierenversagens
Sigler et al. Solute transport in continuous hemodialysis: a new treatment for acute renal failure
EP0804931A3 (de) Lösungen für die Peritonealdialyse und deren Verwendung zum Verringern von Schädigungen an mesothelialen Zellen
Khan et al. Hypokalemia in peritoneal dialysis patients
Mistry et al. Kinetic and Clinical Studies of β2Microglobulin in Continuous Ambulatory Peritoneal Dialysis: Influence of Renal and Enhanced Peritoneal Clearances Using Glucose Polymer
von Lilien et al. Five years' experience with continuous ambulatory or continuous cycling peritoneal dialysis in children
Lamy et al. Comparison between on-line high-efficiency hemodiafiltration and conventional high-flux hemodialysis for polyclonal free light chain removal
Bellomo et al. Management of acute renal failure in the critically ill with continuous venovenous hemodiafiltration
Schmaldienst et al. Angiogenin: a novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation
Samtleben et al. Membrane plasma exchange: principles and application techniques
Kaplan Continuous arteriovenous hemofiltration and related therapies
Brown et al. Peritoneal clearance of theophylline
Davies et al. Clearance studies in patients with acute renal failure treated by continuous arteriovenous haemodialysis
Stefanidis et al. Influence of coagulation parameters on filter running time during continuous venovenous hemofiltration
Gotloib et al. Hemofiltration in severe septic adult respiratory distress syndrome associated with varicella
Paton et al. Cimetidine disposition in patients on continuous ambulatory peritoneal dialysis
Spaia et al. Variability of peritoneal protein loss in diabetic and nondiabetic patients on continuous ambulatory peritoneal dialysis
Von Herrath et al. Good biocompatibility of the polyamide hemofilter
Aberger et al. Differences in drug removal between standard high-flux and medium cut-off dialyzers in a case of severe vancomycin toxicity
JEONG et al. Effect of Erythropoietin on Dialyzer Reuse, Dialysis Efficacy and Other Clinical Parameters
Mehta New developments in continuous arteriovenous hemofiltration/dialysis
Comty et al. Dialytic therapy in the management of chronic renal failure
Horton et al. Continuous arteriovenous hemofiltration: An alternative to hemodialysis
Zobel et al. Continuous arteriovenous renal replacement therapy
Quellhorst et al. Hemofiltration—Technique and clinical application